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AbstrACt
Objectives Individuals with heterozygous familial 
hypercholesterolaemia (FH) are at high risk of developing 
cardiovascular disease (CVD). This risk can be substantially 
reduced with lifelong pharmacological and lifestyle 
treatment; however, research suggests adherence is 
poor. We synthesised the qualitative research to identify 
enablers and barriers to treatment adherence.
Design This study conducted a thematic synthesis of 
qualitative studies.
Data sources MEDLINE, Embase, PsycINFO via OVID, 
Cochrane library and CINAHL databases and grey literature 
sources were searched through September 2018.
Eligibility criteria We included studies conducted in 
individuals with FH, and their family members, which 
reported primary qualitative data regarding their 
experiences of and beliefs about their condition and its 
treatment.
Data extraction and synthesis Quality assessment was 
undertaken using the Critical Appraisal Skills Programme 
for qualitative studies. A thematic synthesis was conducted 
to uncover descriptive and generate analytical themes. 
These findings were then used to identify enablers and 
barriers to treatment adherence for application in clinical 
practice.
results 24 papers reporting the findings of 15 population 
samples (264 individuals with FH and 13 of their family 
members) across 8 countries were included. Data captured 
within 20 descriptive themes were considered in relation 
to treatment adherence and 6 analytical themes were 
generated: risk assessment; perceived personal control 
of health; disease identity; family influence; informed 
decision-making; and incorporating treatment into daily 
life. These findings were used to identify seven enablers 
(eg, ‘commencement of treatment from a young age’) and 
six barriers (eg, ‘incorrect and/or inadequate knowledge 
of treatment advice’) to treatment adherence. There were 
insufficient data to explore if the findings differed between 
adults and children.
Conclusions The findings reveal several enablers and 
barriers to treatment adherence in individuals with FH. 
These could be used in clinical practice to facilitate optimal 
adherence to lifelong treatment thereby minimising the 
risk of CVD in this vulnerable population.
PrOsPErO registration number CRD42018085946.
IntrODuCtIOn
Heterozygous familial hypercholestero-
laemia (FH) is one of the most common 
inherited genetic disorders, estimated to 
affect as many as 1 in 250 individuals world-
wide.1 2 Left untreated, the exposure to 
chronically elevated levels of low density 
lipoprotein cholesterol (LDL-C) from birth 
confers an increased risk of cardiovascular 
disease (CVD),2 3 with approximately 50% 
and 85% of affected women and men, respec-
tively, experiencing a coronary event before 
the age of 65.4 While this risk can be signifi-
cantly reduced with early detection and 
treatment, many affected individuals remain 
at higher risk of premature CVD morbidity 
and mortality.5–9 The most beneficial effects 
of treatment are evident in primary preven-
tion before the onset of CVD.5 10 With 
diagnostic rates as low as 1% in some coun-
tries,11 current efforts are focused on identi-
fying individuals with FH via screening and 
genetic testing programmes.12 13 Treated as 
strengths and limitations of this study
 ► This is the first thematic synthesis of the qualitative 
literature exploring the beliefs and experiences of 
individuals with familial hypercholesterolaemia to 
identify enablers and barriers to treatment adher-
ence that can be targeted in clinical practice.
 ► Robust procedures for conducting a thematic syn-
thesis were adopted, informed by the Cochrane 
Qualitative Research Methods Group guidelines 
and they were reported in line with the Enhancing 
Transparency in Reporting the Synthesis of 
Qualitative Research statement.
 ► The barriers and enablers were identified from 
themes which were representative of all the includ-
ed studies, increasing their validity.
 ► While included studies were conducted across eight 
countries, all were within the developed world which 
could limit the generalisability of the findings.
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outpatients and asked to follow lifelong treatment, it is 
critical to ensure that this increasing patient group are 
able to self-manage their disease. With many patients not 
reaching treatment targets,14–16 it is an area that warrants 
further investigation.
To improve adherence to treatment recommenda-
tions, an understanding of the factors affecting adher-
ence is required. The American Heart Association has 
recognised the need to gain a deeper understanding of 
the experiences of individuals with FH before addressing 
the further identified research gaps.17 Preliminary 
research has found the beliefs and attitudes of patients 
with FH towards the recommended treatment exert a 
significant effect on their intention to engage in these 
behaviours.18 19 Qualitative research can provide further 
insight to how these beliefs and attitudes are developed 
and the nature by which they may influence subsequent 
behaviours.20 Its exploratory nature also allows for the 
identification of other factors influencing an individual’s 
ability and motivation to comply with treatment.21 22
Qualitative research conducted in patients with FH has 
found illness knowledge,23 risk perception,24 a lack of 
symptoms25 and family history of disease26 to influence 
treatment adherence. However, the transferability of 
these findings beyond the sample they are conducted in is 
limited.27 Qualitative syntheses, which bring together the 
findings from individual qualitative studies, can be used 
to gain a more in-depth understanding of the issue and 
identify common themes which are applicable to a wider 
range of contexts.28 29 It is recognised as an important 
source of evidence to inform healthcare interventions 
and policy development30–32 including those targeting 
treatment adherence33–35 and is advocated by the World 
Health Organisation (WHO) and the Cochrane Collabo-
ration Group.28 36 Given the limited literature concerning 
treatment adherence in FH, the results of this synthesis 
will also be compared with the results of research investi-
gating treatment adherence in similar medical conditions.
Objectives
1. Identify how the experiences and beliefs of individuals 
with FH influence their adherence to pharmacological 
and lifestyle treatment recommendations.
2. Explore if these findings differ between children and 
adults.
3. Use the findings to generate new understandings of 
the enablers and barriers to treatment adherence to 
inform clinical practice.
MAtErIAls AnD MEthODs
The methods used for this qualitative synthesis are briefly 
described below with full details available in the published 
protocol37 and on the PROSPERO database (registration 
number CRD42018085946). Minor deviations to the 
protocol were made, outlined in online supplementary 
file 1. The Enhancing Transparency of Reporting the 
synthesis of Qualitative research (ENTREQ) statement38 
has been followed and a checklist is available in online 
supplementary file 2.
search strategy
A comprehensive, systematic and preplanned search was 
conducted to find all available qualitative evidence—full 
details are available in online supplementary file 3.
selection criteria
Participants: Individuals with a clinical or genetic diag-
nosis of heterozygous FH. No restrictions were placed on 
age or history or CVD. Individuals with homozygous FH 
were not included.
Phenomena of interest: The experiences and beliefs of 
individuals with FH, and their family members, regarding 
their condition, its long-term health consequences and 
recommended pharmacological and lifestyle change 
treatment.
Types of studies: Only papers reporting primary qualita-
tive data were included. Questionnaire studies were not 
included. Papers reporting both quantitative and quali-
tative data were included if the qualitative data could be 
independently extracted. Multiple papers reporting find-
ings from the same sample of participants were included 
if they reported unique data.
Intervention/exposure: Treatment was defined as any 
behavioural action undertaken by an individual in an 
effort to manage his/her FH diagnosis.
Setting: No restrictions were placed on the country in 
which study was conduction, nor the location at which 
data were collected from individuals.
Quality appraisal
The methodological quality of the studies was assessed 
using the Critical Appraisal Skills Programme (CASP) 
tool for reviewing qualitative research.39 As the purpose 
of the quality appraisal was to determine the methodolog-
ical strengths and limitations of studies included in the 
synthesis, the lead authors of each paper were contacted 
to obtain further information in an attempt to overcome 
the recognised issued of poor reporting in qualitative 
research. Full details of how this tool was used are avail-
able in online supplementary file 4.
Data extraction
Methodological and contextual information from each 
paper were extracted into a table designed for this review 
by two reviewers independently (FK, JC) after piloting 
in five papers. Two reviewers (FK, AS) independently 
reviewed all text under the results, conclusions and 
discussion headings of all papers, as well as any supple-
mentary files. Any data identified to be relevant to the 
research questions were extracted electronically using 
a tool designed for this review. In instances in which 
multiple papers reported the findings from a single study, 
data from the primary paper PhD theses were extracted 
first, before supplementary publications were reviewed 
for any additional, unique data. Results were compared 
and discussed until agreement was reached.
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Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram. FH, familial 
hypercholesterolaemia.
Data analysis
Thematic synthesis,40 a widely accepted and commonly 
used approach in qualitative syntheses, was used.41 42 It 
involved three stages: line by line coding of the extracted 
data, generation of descriptive themes and development 
of analytical themes. Using NVivo software, two reviewers 
(FK, AS) carried out the coding independently. The subse-
quent stages were carried out collaboratively between 
three reviewers (FK, AS, EW). To enhance transparency, 
full details are available in online supplementary file 5. 
The findings were discussed with three clinicians (JPHS, 
GB, PD) currently providing care to individuals with FH 
to help develop feasible and relevant recommendations 
for clinical practice.
sensitivity analysis
To ensure the quality appraisal results were used in a 
meaningful way,41 43 post-hoc sensitivity analysis was 
carried out by three reviewers (FK, AS, EW) to examine 
the extent to which the synthesis results were affected by 
exclusion of poor quality papers, described in full else-
where.44 It involved examining if any themes were lost 
when each paper was removed from synthesis and eval-
uate if there was a significant impact on the ‘thickness’ of 
findings reported within each theme. ‘Thickness’ refers 
to the depth, scope and context of findings which could 
influence the transferability and credibility of the results 
to the wider FH patient population.45 This was carried 
out through discussion between three reviewers (FK, AS, 
EW).
Patient and public involvement
Patients or members of the public were not involved in 
this study.
rEsults
The titles and abstracts of 990 unique citations identi-
fied by the searches were screened, with 50 progressing 
to screening at the full-text level. Twenty-six papers 
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were excluded at this stage due to the full text not 
being available (n=1), no primary qualitative data being 
presented in the findings (n=6), the study population 
not having a clinical diagnosis of FH or inability to 
selectively extract data from those with a diagnosis in 
a mixed population (n=16) and data not being rele-
vant to the aims of this review (n=3). Multiple papers 
reporting findings from the same sample of individuals 
and three PhD papers,46–48 two of which had supple-
mentary papers published in addition to the originally 
reported theses, were included. Each paper was consid-
ered to be a separate primary paper and referenced 
separately. In total, 24 papers were included in the 
synthesis, comprising 18 original23 25 46–61 and 6 supple-
mentary papers24 26 62–65 reporting the findings of 15 
population samples (figure 1).
Characteristics of studies and participants
In total, 264 individuals with FH and 13 family members 
were involved, aged 8–69 years. Seven papers24 25 46 58 59 62 63 
reported findings from three samples which included 
individuals under 18 years. Four papers reported parental 
views of having children with FH.25 56 58 59 Full character-
istics of the included papers and samples are presented 
in table 1.
Quality appraisal and sensitivity analysis
Appraisal scores of papers ranged from 11 to 20 out of 
20, with 11 rated high, 7 medium and 6 low (table 1). 
The most common methodological limitations uncov-
ered were relating to ethical issues, researcher reflex-
ivity and rigour of data analysis. Consideration of 
a researcher’s potential influence and bias on data 
collection and analysis was critically examined fully in 7 
papers,24 25 46 47 58 62 63 partially in 1023 26 48 50 51 55 57 59 64 65 
and not addressed in 7.49 52–54 56 60 61 Ethical approval 
was obtained, or reasons given for exemption, in all but 
two papers60 61; however, participants were not provided 
adequate information about withdrawal and anonymis-
ation of data processes in a further four papers.25 49 50 58 
The data analysis was carried out by one researcher only 
in seven papers23 26 47 48 56 64 65 and it was unclear if more 
than one person was involved at each stage of analysis in 
four papers.51 52 60 61
Eight lead authors responded to our request for further 
information, providing information for 16 of the 24 
papers. Five of the six papers rated as low quality were 
papers for which the author did not respond. This reflects 
our belief that low ratings may be reflective of poor 
reporting rather than poor methodology, supporting 
our decision not to exclude papers. The sensitivity anal-
ysis carried out found that the removal of the six poor 
quality papers had no significant effect on the synthesis 
findings—in both the descriptive and analytical themes 
uncovered and the depth of the findings. More detailed 
information of methodological and transferability issues 
is available in online supplementary file 4.
Data analysis
Six analytical themes were derived from the findings 
captured by 20 identified descriptive themes, as displayed 
in table 2 alongside illustrative quotes. Table 3 shows the 
occurrence of the descriptive themes within the extracted 
data from the 24 papers. While each analytical theme has 
a direct influence on treatment adherence, they are not 
exclusive in nature and inter-theme relationships are 
evident as displayed in the thematic schema in figure 2. 
Additionally, some themes by their integrative nature 
had a greater influence on treatment adherence as indi-
cated by the shaded boxes. There were insufficient data 
regarding children and young people to explore whether 
the findings differed from adults.
Seven enablers and six barriers to treatment adherence 
(table 4) were uncovered during the analysis of these 
themes and are described alongside the analytical themes 
below. In this section ‘treatment’ refers to both lifestyle 
and medication behaviours, unless otherwise specified.
Analytical themes
Risk assessment
Individuals lived experience of their disease, coupled 
with their beliefs concerning its known risks, increased 
or decreased their sense of vulnerability to its long-term 
health consequences. Knowledge of how FH had affected 
family members was the most prevalent factor consid-
ered by individuals when assessing their risk. Individ-
uals with lived experience of a family member being ill 
or dying prematurely due to FH had a heightened sense 
of risk.46 48 49 52 55 56 58–62 Individuals unaware of FH in 
their families or with family members living a life unaf-
fected by its consequences perceived themselves at lower 
risk46 52 56 58 61 62: ‘My dad’s now in his 70s…it’s not some-
thing I feel particularly threatened about having.’56
As FH does not ‘make you feel ill’,52 individuals found 
having FH ‘easy to forget, and easy not to take seriously.’47 
This was salient among younger individuals without 
existing CVD symptoms23 25 47 48 58 59 65 for whom ‘…choles-
terol always comes last. It will never be a focus until some-
thing happens to me.’47 Older individuals who had lived 
through, or were currently experiencing CVD, perceived 
themselves at higher risk.23 56 61 62 Others framed their 
perception of risk in the context of the risk they believed 
other diseases presented, concluding that FH health 
consequences were not as serious23 47 48 51 53 54 61: ‘I didn’t 
think it was life threatening, like being told you’ve got 
cancer.’23
For the majority of individuals, their risk assessment 
led to a perception that FH did not present a great risk 
to their current or long-term health.23 47–49 51 56 59–61 This 
mismatch between the perceived and actual risk has been 
identified as a barrier to treatment adherence.
Perceived personal control of health
Individuals acknowledged the threat that FH posed to 
their health, but there was a widely held belief that they had 
the ability to modify their own personal risk.24 47 49 51 53–62 
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Table 2 Analytical themes and their composite descriptive themes with illustrative quotes
Analytical theme Descriptive themes
Illustrative quotes from participants (first 
order)
Illustrative interpretations from authors 
(second order)
Risk assessment FH is a silent disease ‘Not a condition that has any symptoms, 
that makes you feel ill or anything.’52
‘The majority of interviewees did not look 
on the condition as a disease…If they 
were not affected by a cardiac disease…
they regarded themselves as healthy.’49
Family history modifies 
perception of FH-related 
threat to health
‘I’m not going to get past sixty. Dad never 
got past sixty.’53
‘To them, reaching the age of death of a 
parent with FH was anticipated with fear 
of having a heart attack themselves.’60
FH is not as threatening to 
health as other conditions
‘Its not that bad….Its not like having 
something like Huntington’s or something 
like that.’51
They mentioned conditions with more 
drastic consequences such as allergies, 
epilepsy or diabetes.’47
Perceived personal control 
of health
FH is a manageable 
condition
‘Well it’s treatable isn’t it by diet and drugs. 
It’s not something that’s incurable.’48
‘FH carrier children demonstrated high 
feelings of control over their condition.’59
Individuals feel personally 
responsible for managing 
their FH
‘It means you could be in danger of like 
what could possibly happen like in the 
future if you don’t change anything.’58
‘FH patients have a strong desire to 
empower themselves in order to improve 
their own health.’50
FH medication is effective ‘I believe that as I am taking the pills that 
my risk of heart attack is no greater than 
anyone else of my age or weight.’61
‘Preventative medical treatment built 
confidence in the potential for living a 
long life.’55
FH lifestyle treatment 
viewed as less important 
than medication
‘I could never get that down no matter how 
much dieting or exercise I do…so it can 
only be reduced through medication.’48
‘Many tended to devalue the importance 
of lifestyle changes in controlling FH and 
place their hope in medication.’23
Disease identity Importance of 
establishing that high 
cholesterol levels are not 
self-inflicted
‘It enables me to emphasise that it is not 
my fault, that it’s something inherited.’62
‘They always described FH as a 
hereditary condition to underline that 
their cholesterol issues were not due to 
unhealthy lifestyle.’60
Receiving genetic 
diagnosis provides 
certainty
‘I guess it is a relief in a funny way because 
I had an answer to what was quite a 
surprising medical condition that I had…
so at least I know now and can take 
preventative measures.’54
‘It provided an aetiological explanation 
and diagnostic label, confirmed current 
risk management practices…’24
The influence of family Desire to protect children ‘We want to help him…(so) we have 
decided to give him statins until he is 16…
we’ve covered him until he’s old enough to 
decide for himself.’56
‘In fact, the main concern for the affected 
parents appeared to be the well-being of 
their children…’49
Parental influence 
on treatment related 
behaviours
‘My parents, specifically my mom, were 
really integral in teaching us types of food 
to eat.’25
‘AYAs expressed how their perceptions of 
their parents experience have influenced 
their perceptions of the respective 
treatment options.’58
FH and its treatment 
become normalised within 
families
‘Since I grew up with FH and had a 
relatively good diet and good habits and 
routines, it makes it easier.’47
‘FH carrier children typically reported it 
had become habit to maintain a healthy, 
non-fat diet. Commonly the whole family, 
including the non-carriers, kept to the 
same diet restrictions.’59
Informed decision making HCP interactions ‘My daughter. I don’t think she really 
understood what (high cholesterol) really 
meant until she came here and talked with 
doctor.’58
‘The doctors presentation of FH, however, 
influenced all patients perceptions of the 
risk and severity of the diagnosis.’60
Inadequate and/or 
incorrect knowledge 
about FH and treatment
‘in the newspapers, the stories that you 
cut out butter, red meat, etc, and you’ll be 
okay.’61
‘Many informants still had unanswered 
questions or were felt to lack relevant 
knowledge.’49
Concerns about side 
effects of FH medication
‘Would I be able to have children at all after 
taking all these medicines for years?’49
‘Parents reported having strong concerns 
about statin treatment in children, not 
only because of their long-term safety but 
also potential side effects.’56
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Analytical theme Descriptive themes
Illustrative quotes from participants (first 
order)
Illustrative interpretations from authors 
(second order)
Incorporating treatment 
into daily life
FH and its treatment does 
not have big impact on life
‘You don’t have to plan your life around it. 
You don’t have to wonder, can you have 
children or not.’51
‘FH was not viewed as a significant 
burden, but more of a lifestyle 
adjustment, involving a healthy diet, 
exercise, and statin treatment from an 
early age.’56
Balancing FH treatment 
with other competing 
priorities
‘Our two children, who were often ill….My 
husband…travelled all the time, so I almost 
had more than I could put up with at that 
moment.’62
‘Young adults also articulated challenges 
maintaining diet and exercise regimes 
while adjusting to a new routine and 
environment at college or in workforce.’25
Lifestyle advice treatment 
is restrictive and difficult 
to follow
‘I’ve changed my diet as much as I can… 
don’t want to bother too much and 
speculate, live an unworthy life and diet at 
the age of seventy. I’d rather be happy and 
die when I’m fifty.’24
‘Making dietary changes had been the 
worst aspect of their condition, and this 
included people who already had CHD.’62
Social implications of 
following FH treatment
‘Some people comment on the things I eat. 
And then I’m like ‘well actually I have to 
eat this because I’ve got FH and I have to 
watch my diet.’54
‘10 young adults articulated how 
concern over peers’ opinions or overt 
peer pressure-restricted social activities 
centred around eating.’25
Desire for further support 
and guidance
I think having the resources (would make 
it easy to adhere to lifestyle treatment)…
like seeing a nutritionist that can give you 
options….’25
‘…expressed a desire to be able to 
access educational resources in one 
place and for a way to reach out to others 
who could provide solidarity, comfort and 
aid with management of FH.’50
AYA, adolescent and young adult; CHD, cardiovascular heart disease; HCP, healthcare professional.
Table 2 Continued
They recognised that this required active engagement 
with treatment23–25 47 49–51 53–56 58 61 62 and held themselves 
accountable for managing their disease23–25 47–51 53–58 60–62 
experiencing a ‘bad conscience’49 and ‘guilt’63 when they 
did not meet the expectations they had set themselves. 
Treatment was perceived to be effective24 47 49 51 53–62 with 
individuals viewing FH as ‘treatable’48 and ‘controllable’.23 
In particular, medication was regarded by individuals 
to be a mandatory and effective component of treat-
ment.24 47 49 51 53–62 They believed FH could be ‘solved’59 
with medication and lead to achievement of cholesterol 
levels ‘like most people’.23 While individuals spoke of their 
efforts to change their lifestyle behaviours,24 25 47 49 51 53–62 
many believed their cholesterol levels would not be ‘radi-
cally changed’61 by doing so47 48 58 60 as ‘doesn’t matter 
what I eat or how much exercise I’m still going to have 
high cholesterol without tablets’.23
This confidence in the ability to successfully self-manage 
their condition was identified as an enabler to treatment 
adherence. The perceived effectiveness of medication 
led to a devaluing of the importance of following lifestyle 
treatment,23 47 48 57 58 60 and this prioritisation of medica-
tion was identified as a barrier to adhering to lifestyle 
treatment.
Disease identity
Individuals placed great importance, especially in social 
situations, to emphasis that they were ‘not to blame’60 
for their high cholesterol.24 26 48 50 51 53 54 57 60 61 63 High 
cholesterol was associated with unhealthy lifestyles and 
individuals wished to distance themselves from this 
negative connotation.24 48 54 57 60 61 63 A positive genetic test 
provided ‘a definitive’,51 rather than a possible, explana-
tion for their high cholesterol50 53 54 and positively influ-
enced individuals’ perceptions and behaviours.24 50 51 53 54 
If individuals had been following treatment of their own 
volition before the diagnosis, it helped ‘reaffirm their 
commitment’53 to treatment.51 54 If they had been previ-
ously unaware of their condition, it prompted them to 
seek treatment53 56: ‘I know now and can take preventative 
measures’.54 Therefore, receiving a formal diagnosis was 
identified as an enabler to treatment adherence as being 
given a medical explanation empowered individuals to 
take control of their condition through engaging with 
treatment.
Family influence
Parents expressed a high level of concern about the well-
being of their affected children25 48 50 51 53 56 58 59 and this 
parental responsibility to care for children was identi-
fied as another enabler of treatment adherence. They 
assumed responsibility to ensure their children adhered 
to medical and lifestyle treatment,25 48 50 51 53 56 58 59 taking 
action to ‘bring them up with healthy eating habits’51 and 
‘make sure that they take their medication’.48 This involve-
ment was reflected in the finding of individuals attrib-
uting their current treatment knowledge and behaviours 
to their parents47–49: ‘everything I’ve learnt from home’.47 
Parents also made treatment-related decisions on their 
behalf25 48 50 53 58 59 until they were ‘old enough to decide.’56 
As such, the early adulthood years presented a challenge 
for treatment adherence as the young adults transitioned 
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Figure 2 Thematic schema illustrating influence of analytical 
themes on treatment adherence.
from being under the care of their parents to assuming 
responsibility for their behaviours.25 47
Growing up surrounded by family members following 
treatment recommendations and establishing healthy 
behaviours from a young age was found to instil lifelong 
habits in individuals.25 47 48 56 58 59 Those who had grown up 
from a young age alongside diagnosed family members 
spoke of their condition and its treatment as something 
that had become ‘normalised’47 as it was all they had 
ever known.25 48 56 58 59 Those who had parents who had 
bad experiences of medication were apprehensive about 
taking tablets,58 but for many it led to the view that taking 
medication was ordinary56 and not a ‘big deal’.58
Two enablers to treatment adherence were identified 
from these findings: commencement of treatment from 
a young age and having other family members following 
similar treatment regimes.
Informed decision-making
Individuals lacked an in-depth understanding of their 
disease and its treatment,23–25 47–51 56–59 61 with many 
having ‘unanswered questions’49 and requesting more 
information.25 49–51 Misconceptions and false informa-
tion regarding the role of treatment for FH were prev-
alent24 25 47–49 51 56–59 61: ‘you can actually eat a lot of fat 
and the medicine takes care of it.’23 Individuals were 
worried about the longer term impact of statin therapy 
on their and their children’s health49 58 as ‘it is a recent 
drug, and you don’t know what the long term effect could 
be.’56 Lived experience of side effects were reported by 
some individuals49 58 60 and many more were fearful of 
developing them in the future55 56 58 as ‘many others have 
severe side effects from what I’m taking’.60 This incorrect 
and/or inadequate knowledge of treatment advice and 
concerns over the short-term and long-term use of lipid 
lowering medication were identified as barriers to treat-
ment adherence.
Individuals frequently mentioned their 
encounters with healthcare professionals 
(HCPs),23 24 46–48 50 52 53 56 57 59 60 viewing them as playing a 
‘big role’25 in their ‘team approach’58 to the management 
of their FH. Regardless of whether individuals recalled 
these encounters in a positive24 25 47 48 50 56 58 or nega-
tive24 46 47 56 60 light, these interactions and relationships 
with HCPs influenced their understanding of FH and its 
treatment.
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Table 4 Identified enablers and barriers to treatment adherence
Enablers Barriers
Other family members following treatment regime Mismatch between perceived and actual risk
Commencement of treatment from a young age Concerns over the use of lipid lowering medication
Parental responsibility to care for children Prioritisation of medication over lifestyle treatment
Confidence in ability to successfully self-manage their condition Lifestyle treatment is difficult to comply with
Receiving formal diagnosis of FH Prioritisation of other life events
Practical resources and support for following lifestyle treatment Inadequate and/or incorrect knowledge of treatment advice
A positive relationship with healthcare professional   
FH, familial hypercholesterolaemia.
Integrating treatment into daily life
Individuals did not feel they had to make many changes to 
their everyday life as a result of their diagnosis.23 47–49 51 54 61 
Their disease did not hinder them from ‘living the life 
they wanted’47 or require consideration when making life 
decisions23 47 49 54 61 such as having children.48 51However, 
when faced with other commitments, such as family 
and career obligations, individuals found it more diffi-
cult.23 25 47 49 54 60 62 During these periods, individuals tended 
to be less focused on managing their disease viewing it as 
something they could pick up again when they had more 
time and energy.23 25 47 56 62 This prioritisation of other life 
events over the self-management of condition was identi-
fied as a barrier to treatment adherence.
The treatment recommendations were perceived to be 
simple to follow and to have little impact on their quality 
of life (QOL).23 47–49 51 53–56 61 However, this perception 
is in stark contrast to the actual lived experiences of 
following treatment—especially the lifestyle recom-
mendations. Dietary advice was perceived to be restric-
tive and interpreted by individuals to mean they could 
not eat their favourite foods24 25 47 48 57 59 or enjoy social 
occasions24 25 54 57 59 60: ‘I won’t bother eating food I don’t 
like, just to follow a certain diet’.47 Additionally, individ-
uals were concerned about the opinions of their peers 
in social situations in which they felt they had to make 
certain dietary choices.25 47 48 59 60 These findings were 
prominent among younger individuals.25 47 59As a result, 
the dietary advice was the ‘most difficult aspect’49 of treat-
ment, with many reporting they struggled to follow them 
at all times.23–25 47 48 57 59 60 This finding of dietary advice 
being perceived as difficult to follow was identified as a 
barrier to adherence.
Reflective of the difficulties faced when trying to follow 
treatment guidelines, individuals expressed a need for 
additional information23 49 50 56 and ‘guidelines in order 
to help you start that change’.25 Some sought additional 
information from their HCPs,23 25 49 50 56 while others called 
for practical advice and educational resources,25 49 50 56 as 
‘everyone knows the theory, but putting it to practice is 
quite hard’.23 From this, practical resources and support 
for following lifestyle treatment advice was identified as 
an enabler to treatment adherence.
DIsCussIOn
This synthesis has produced new insights into the factors 
influencing treatment adherence in FH which have impli-
cations for clinical practice and future research.
We found that individuals did not perceive FH as a 
threat to their health except in those who had experi-
enced symptoms of CVD or had a family history of FH-re-
lated CVD, as previously reported by others.66–69 This low 
perception of risk may be the result of the disease being 
relatively symptomless and the adverse consequences too 
far in the future to comprehend. This idea is reinforced by 
studies reporting heightened perceived risk among older 
individuals70 and young adults perceiving their health 
to be average or above that of the general population.16 
The minimal threat to health may explain the findings 
that being diagnosed with FH does not increase psycho-
social dysfunction in children,71 72 nor negatively impact 
on self-reported QOL or rates of depression and anxiety 
in adults.73–76 While these findings are positive, individ-
uals who do not view their disease as a serious threat 
may be less motivated to adhere to treatment, which may 
explain the findings of higher self-reported medication 
adherence in older individuals77 78 and high non-adher-
ence rates in individuals under 36 years.79 These findings 
are concerning as individuals who do not adhere fully 
to treatment have been found to have higher levels of 
LDL-C.77 79 80 Furthermore, while treatment has substan-
tially reduced the risk of CVD, individuals still remain 
at a higher risk than the general population.9 81 82 This 
may be a consequence of LDL-C targets not being met by 
large numbers of treated adults15 16 79 80 83 and children84 85 
and/or the presence of other risk factors independently 
associated with CVD.86 87
Our findings suggest this low-risk perception may 
be mediated by beliefs that the risks are avoidable 
through effective treatment, in line with previous 
research.16 66 72 88 These beliefs have been found to posi-
tively influence attitudes towards medication, increasing 
self-reported intentions to comply with medication19 
and rates of adherence.89 However, individuals’ attitudes 
toward treatment behaviours may have a greater influ-
ence on their intention to engage in treatment than 
their beliefs.18 Our findings of negative attitudes towards 
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certain aspects of treatment are therefore important to 
explore. We found individuals to perceive dietary recom-
mendations as restrictive and impacting on their QOL, 
as have others.72 90 Some also believed they were unnec-
essary if taking medication, likely explaining low uptakes 
of lifestyle treatment compared with medication.66 91 We 
also found negative attitudes towards medication due to 
side effects and anxieties about long-term safety, similar 
to others.16 83 92 In contrast to these studies, we found 
anxiety about the development of side effects and compli-
cations of long-term use to be more prevalent than lived 
experience of side effects. These negative attitudes are 
surprising as the dietary recommendations do not differ 
substantially from those for the general population and 
the safety and tolerability of statins have been demon-
strated in adults93 and children.94–96
Our finding of widespread inadequate knowledge of 
the treatment recommendations may explain the nega-
tive attitudes. It has been reported previously that aware-
ness of the role of PA in treatment is low,97 and while 
individuals are mindful of the need for dietary treatment, 
little is known about the depth of this knowledge.72 90 97 
This finding may be the result of the inconsistency in 
treatment advice provided with many not receiving the 
recommended lifestyle advice91 98 99 or medication treat-
ment83 85 91 98 100 101 and for those that do, it is often not 
provided by HCPs with specialist FH knowledge.91 99 
As a result, we found many individuals are left wanting 
more information about treatment, in line with previous 
research.91 97 This is concerning as many report using the 
internet to search for such information91 which cannot be 
easily regulated and may be fuelling our further finding 
of a high prevalence of incorrect knowledge. Further-
more, individuals may be falsely interpreting negative 
media coverage of statin medication102 to be relevant 
to their condition. This may be negatively influencing 
adherence to treatment as concerns about general medi-
cation overuse have been found to be heavily influential 
in shaping attitudes towards FH medication19 Ensuring 
individuals have a comprehensive and factually correct 
understanding of the treatment recommendations is 
therefore essential to optimise adherence.
As this synthesis highlighted that parents take respon-
sibility for their childs’ treatment, it is important to 
ensure they are knowledgeable about the recommenda-
tions to help their children develop healthy habits from 
a young age. Previous research has found that children 
who follow dietary guidelines from a young age have 
more positive attitudes towards this aspect of treatment71 
and have improved dietary intakes in childhood103–105 
which are maintained into young adulthood.106 Further-
more, forgetfulness is frequently reported as a reason 
for medication non-adherence16 72 77 78 80 92 and starting 
treatment at a young age may help overcome this by 
instilling a routine, as found by others.107 It is also 
important to ensure that when individuals reach an age 
where they become responsible for their own care, they 
themselves are equipped with the relevant knowledge 
to continue to make informed decisions. While there 
were insufficient data to draw conclusions about best 
practice for this age group, it appears that transitioning 
from living at home, adjusting to new routines and 
prioritising other things in life are common barriers to 
be targeted.25 47
Our findings also highlight the importance of receiving 
a genetic confirmation of FH. Receiving a medical 
diagnosis empowered individuals to take control of 
their condition, providing motivation to continue or 
commence medication and lifestyle treatments. The 
positive influence of diagnosis on medication efficacy 
beliefs and adherence has been reported in previous 
research.67 68 108 109 However, in contrast to our findings, 
it has been reported that positive genetic results have 
either no effect68 or weaken beliefs108 regarding the effi-
cacy of lifestyle treatment. However, in both cases the 
changes in beliefs did not have a negative impact on their 
actual behaviours. Given our further finding that individ-
uals find medical diagnosis useful in social situations, a 
common identified barrier to adhering to dietary recom-
mendations, it may be that genetic diagnosis exerts posi-
tive effect on adherence beyond its influence of illness 
and treatment beliefs.
strengths and limitations
Our thematic synthesis adhered to ENTREQ guidelines 
and used transparent and robust methodology. The 
comprehensive search strategy, involvement of more than 
one researcher at each stage of analysis, input from clini-
cians to corroborate the interpretation of the results and 
detailed appraisal of the included studies strengthen our 
findings. The analytical themes generated were produced 
from descriptive themes that were each evident across 
a large number of the included papers. The synthesis 
included data from 264 individuals with FH and 13 family 
members across 8 countries, encompassing a wide range 
of ages, duration of diagnoses, primary and secondary 
CVD prevention and regional differences in healthcare 
provision. However, all individuals were from developed 
countries, the majority had high education levels and 
there were few from ethnic minority groups. This may 
limit the generalisability of the findings to all individuals 
with FH. Furthermore, the majority were recruited from 
lipid clinics and their beliefs may not reflect those opting 
out of treatment for their condition. Lastly, there were 
insufficient papers to explore if the factors influencing 
treatment adherence differ between adults and children 
with FH and care should be taken when extrapolating 
results to younger individuals.
Implications for clinical practice
We have identified seven enablers and six barriers to 
treatment adherence (table 4) to be considered by 
any HCP delivering advice to individuals with FH and 
have produced the following 12 suggestions for clinical 
practice:
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1. Ensure individuals are aware of the risk to their 
health, without instilling fear through emphasising 
the effectiveness of medical and lifestyle treatment.
2. Where possible, ensure all individuals receive genetic 
confirmation of their condition.
3. Communicate that despite the asymptomatic nature 
of the condition, adhering to treatment from a young 
age will deliver the greatest benefits to health.
4. Discuss medication within an FH context, emphasis-
ing its necessity and distinguishing it from the use 
of medication in treatment of other causes of high 
cholesterol.
5. Provide reassurance that medication is safe and side 
effects uncommon, with reference to relevant clinical 
guidelines indicating their safety for use by children 
highlighted to parents.
6. Inform patients that side effects are specific to each 
type of medication and encourage discussion of any 
problems so alternative medications can be offered.
7. Communicate dietary advice as being a lifestyle 
change rather than a restrictive diet with advice tai-
lored to the individual needs and preferences of each 
individual.
8. Ensure individuals have a factually correct under-
standing of the dietary recommendations and pro-
vide credible resources individuals can access if they 
require further support or guidance.
9. The benefits of adhering to lifestyle treatment for 
management of their disease and their overall well-be-
ing should be revisited at each clinic appointment.
10. Treatment should begin early, with parents advised 
that prior to medication, dietary recommendations 
can be followed from the age of 5. Non-affected 
family members can also be encouraged to follow 
guidelines, facilitating a family-based approach to aid 
adherence.
11. Treatment advice to be provided in family-based clin-
ics if possible, or ensure adult and paediatric services 
are closely linked.
12. Adolescent patients to be offered opportunity to tran-
sition to an adult clinic between the ages of 16 and 18 
to take responsibility for their own treatment before 
they leave home.
Comparison with treatment adherence in similar medical 
conditions
The limited literature regarding treatment adherence 
in FH makes comparison of findings with the present 
synthesis difficult. However, extensive research has been 
conducted into treatment adherence for other chronic 
conditions which are also asymptomatic in the early stages 
such as hypertension, high cholesterol from non-genetic 
conditions and type 2 diabetes mellitus, for which treat-
ment adherence rates are also low.110 111 While it is beyond 
the scope of this review to compare and contrast the 
findings in detail, overall the enablers and barriers were 
similar to those found to exist for individuals following 
treatment for these similar conditions. For example, 
negative perceptions of medication, beliefs that treat-
ment is not necessary due to lack of symptoms, medica-
tion side effects and a lack of knowledge about treatment 
and/or disease were identified as barriers to adherence 
for those advised treatment to manage risk factors for the 
primary and secondary prevention of CVD.112–114 Further-
more, similar findings have been reported in individuals 
with type 2 diabetes mellitus.115–117 A unique finding of 
the present synthesis, however, was that starting treatment 
from a young age and being surrounded by other family 
members following treatment facilitates adherence. This 
is reflective of the genetic inheritance pattern in which 
an individual will always have one affected parent, which 
is uncommon in other chronic conditions. Although 
support from family members, and the involvement 
of parents, has been identified as an enabler to treat-
ment adherence for individuals with type 2 diabetes 
mellitus,115 118 119 the adherence behaviours that parents 
with FH model to family members are of particular impor-
tance in the treatment of FH.
Future research
With treatment most effective when started at a young 
age,6 10 85 and our findings of a positive effect on later 
life adherence, further qualitative research exploring the 
perspectives of children is required to allow HCPs to tailor 
advice to support maximal adherence during this crucial 
period. The findings of widespread inadequate and/or 
incorrect knowledge of the treatment recommendations 
warrant investigation into what advice is being given and 
by whom. As individuals who have self-selected to receive 
treatment have concerns about medication, it is likely that 
there are many individuals opting not to receive treat-
ment for themselves or their child due to these concerns. 
Future research is needed to explore their perceptions 
to develop effective interventions that could encourage 
them to seek treatment.
COnClusIOns
This qualitative evidence synthesis has systemati-
cally reviewed and synthesised the available evidence 
concerning the experiences and beliefs of individuals 
with FH regarding their condition and its treatment. It 
has uncovered several enablers and barriers that are to 
be used in clinical practice to facilitate optimal treatment 
adherence in this high-risk clinical population group. It 
has also highlighted significant research gaps which need 
to be addressed to gain a more comprehensive under-
standing of how these individuals can be supported to 
adhere to lifelong treatment.
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